Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611044 | 0.82 | RET (0.55) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL1129258 | 0.82 | ALDH1A1 (0.49) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL21442708 | 0.79 | XDH (0.52) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL24983884 | 0.75 | CYP1A2 (0.33) | CYP1A2ALDH1A1PDPK1 | |
| SCHEMBL10226489 | 0.75 | ALDH1A1 (0.56) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL22662122 | 0.75 | CYP1A2 (0.55) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| Allopurinol SCHEMBL9245969 | 0.72 | CYP1A2 (0.54) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL21275551 | 0.69 | RET (0.52) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL12352811 | 0.69 | ALDH1A1 (0.53) | CYP1A2ALDH1A1PDPK1RETPI4KA | |
| SCHEMBL10094121 | 0.69 | PDPK1 (0.66) | CYP1A2ALDH1A1PDPK1RETPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | CYP1A2 2476/4885ALDH1A1 1946/4885PDPK1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.